Evidence map›Paper›PMID 35530749›Full record

ArticleACS omega2022

Neutralizing Effect of Synthetic Peptides toward SARS-CoV-2.

Pedro F N Souza, Maurício F vanTilburg, Felipe P Mesquita, Jackson L Amaral, Luina B Lima, Raquel C Montenegro, Francisco E S Lopes, Rafael X Martins, Leonardo Vieira, Davi F Farias and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Future microbiology · 2024
    Article
  4. Review
  5. No Chance to Survive:Antibiotics (Basel, Switzerland) · 2023
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Pedro F N SouzaDepartment of Biochemistry and Molecular Biology, Federal University of Ceará, Av Mister Hull, S/n-Pici, P.O. Box 60440-593, Fortaleza, Ceará 60020-181, Brazil.ORCID https://orcid.org/0000-0003-2524-4434
Maurício F vanTilburgBiotechnology and Molecular Biology Laboratory, Renorbio, State University of Ceará, Av. Dr. Silas Munguba, 1700-Itaperi, P.O. Box 60714-903, Fortaleza, Ceará 60020-181, Brazil.
Felipe P MesquitaDrug Research and Development Center, Department of Physiology and Pharmacology, Federal University of Ceará, Rua Coronel Nunes de Melo 100, P.O. Box 60430-275, Fortaleza, Ceará 60020-181, Brazil.
Jackson L AmaralDepartment of Biochemistry and Molecular Biology, Federal University of Ceará, Av Mister Hull, S/n-Pici, P.O. Box 60440-593, Fortaleza, Ceará 60020-181, Brazil.
Luina B LimaDrug Research and Development Center, Department of Physiology and Pharmacology, Federal University of Ceará, Rua Coronel Nunes de Melo 100, P.O. Box 60430-275, Fortaleza, Ceará 60020-181, Brazil.
Raquel C MontenegroDrug Research and Development Center, Department of Physiology and Pharmacology, Federal University of Ceará, Rua Coronel Nunes de Melo 100, P.O. Box 60430-275, Fortaleza, Ceará 60020-181, Brazil.
Francisco E S LopesDepartment of Biochemistry and Molecular Biology, Federal University of Ceará, Av Mister Hull, S/n-Pici, P.O. Box 60440-593, Fortaleza, Ceará 60020-181, Brazil.
Rafael X MartinsLaboratory for Risk Assessment of Novel Technologies (LabRisk), Department of Molecular Biology, Federal University of Paraiba, Campus I Lot. Cidade Universitaria, P.O. Box 58051-900, João Pessoa, Paraíba 58051-900, Brazil.
Leonardo VieiraLaboratory for Risk Assessment of Novel Technologies (LabRisk), Department of Molecular Biology, Federal University of Paraiba, Campus I Lot. Cidade Universitaria, P.O. Box 58051-900, João Pessoa, Paraíba 58051-900, Brazil.
Davi F FariasLaboratory for Risk Assessment of Novel Technologies (LabRisk), Department of Molecular Biology, Federal University of Paraiba, Campus I Lot. Cidade Universitaria, P.O. Box 58051-900, João Pessoa, Paraíba 58051-900, Brazil.
Ana C O Monteiro-MoreiraSchool of Pharmacy, University of Fortaleza, Av. Washington Soares, 1321, Edson Queiroz, P.O. Box 60811-905, Fortaleza, Fortaleza, Ceará 60811-690, Brazil.
Cleverson D T FreitasDepartment of Biochemistry and Molecular Biology, Federal University of Ceará, Av Mister Hull, S/n-Pici, P.O. Box 60440-593, Fortaleza, Ceará 60020-181, Brazil.
Arnaldo S BezerraBiotechnology and Molecular Biology Laboratory, Renorbio, State University of Ceará, Av. Dr. Silas Munguba, 1700-Itaperi, P.O. Box 60714-903, Fortaleza, Ceará 60020-181, Brazil.
Maria I F GuedesBiotechnology and Molecular Biology Laboratory, Renorbio, State University of Ceará, Av. Dr. Silas Munguba, 1700-Itaperi, P.O. Box 60714-903, Fortaleza, Ceará 60020-181, Brazil.
Débora S C M Castelo-BrancoDepartment of Pathology and Legal Medicine, Federal University of Ceará, Rodolfo Teófilo, P.O. Box 60010-681, Fortaleza, Ceará 60020-181, Brazil.
Jose T A OliveiraDepartment of Biochemistry and Molecular Biology, Federal University of Ceará, Av Mister Hull, S/n-Pici, P.O. Box 60440-593, Fortaleza, Ceará 60020-181, Brazil.ORCID https://orcid.org/0000-0003-1207-1140
Universidade Federal do Ceará · BRUniversidade Estadual do Ceará · BRUniversidade Federal da Paraíba · BRUniversidade de Fortaleza · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The outbreak caused by SARS-CoV-2 has taken many lives worldwide. Although vaccination has started, the development of drugs to either alleviate or abolish symptoms of COVID-19 is still necessary. Here, four synthetic peptides were assayed regarding their ability to protect Vero E6 cells from SARS-CoV-2 infection and their toxicity to human cells and zebrafish embryos. All peptides had some ability to protect cells from infection by SARS-CoV-2 with the D614G mutation. Molecular docking predicted the ability of all peptides to interact with and induce conformational alterations in the spike protein containing the D614G mutation. PepKAA was the most effective peptide, by having the highest docking score regarding the spike protein and reducing the SARS-CoV-2 plaque number by 50% (EC

Identifiers

PMID35530749
PMCPMC9063117
OpenAlexW4229458554

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.